Venous Thromboembolism Market Forecast 2025–2034: Where Businesses Should Invest Next

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Venous Thromboembolism Market From 2025 To 2034?

The venous thromboembolism market has experienced consistent growth over recent years. It is projected to expand from $2.44 billion in 2024 to $2.53 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 3.9%. This historical expansion is attributable to several factors, including an aging population, breakthroughs in anticoagulants, supportive reimbursement policies, and a rise in investments.

The venous thromboembolism market is anticipated to experience consistent expansion over the coming years. It is projected to reach $3.02 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 4.4%. Factors such as global healthcare access, genetic risk assessment, telemedicine and remote monitoring, along with patient education and support, are driving this growth during the forecast period. Key developments expected within this forecast timeframe encompass extended thromboprophylaxis, novel oral anticoagulants, personalized treatment plans, and advanced diagnostic imaging.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13001&type=smp

Which Drivers Are Supporting Growth Of The Venous Thromboembolism Market?

The expansion of healthcare infrastructure is anticipated to fuel the growth of the venous thromboembolism market moving forward. The healthcare industry consolidates economic sectors that deliver products and services aimed at curing, preventing, rehabilitating, and offering palliative care to patients. The growth within the healthcare industry fosters the development of institutional infrastructure, policies, practices, and educational programs essential for supporting VTE prevention protocol implementation. For example, in May 2023, the American Health Care Association reported an increase in US hospitals to 6,129, up from 6,093 in 2022. Furthermore, the Office for National Statistics stated in May 2023 that UK healthcare expenditure amounted to approximately £292 billion, showing a nominal rise of 5.6%. Moreover, long-term health and social care spending experienced a real-terms increase of 2.8% in 2022. Thus, the expanding healthcare industry is a key factor driving the growth of the venous thromboembolism market.

What Are The Leading Segments Analyzed In The Venous Thromboembolism Market?

The venous thromboembolismmarket covered in this report is segmented –

1) By Type: Deep Vein Thrombosis; Pulmonary Embolism; Other Types

2) By Treatment: Anti-Clotting Medications; Mechanical Devices; Thrombolytic Therapy; Other Treatment

3) By End Users: Hospitals; Homecare; Specialty Centers; Other End Users

Subsegments:

1) By Deep Vein Thrombosis (DVT): Proximal DVT; Distal DVT; Asymptomatic DVT

2) By Pulmonary Embolism (PE): Acute PE; Chronic PE; Submassive PE

3) By Other Types: Thrombophlebitis; Superficial Vein Thrombosis; Post-Thrombotic Syndrome

Which Trends Are Impacting The Venous Thromboembolism Market?

Leading companies in the venous thromboembolism market are developing innovative anticoagulant drugs and solutions to maintain their competitive position. Advancements in anticoagulants have the potential to lead to the creation of more effective medicines capable of preventing or treating venous thromboembolism. For instance, in September 2022, Anthos Therapeutics, a US-based clinical-stage biotherapeutics company, obtained regulatory approval for its abelacimab anticoagulant medicine from the Food and Drug Administration (FDA), a US-based government agency. This new medicine is a fully human monoclonal antibody and is indicated for preventing stroke and systemic embolism in patients with atrial fibrillation. The newly developed, once-monthly, dual-acting antibody abelacimab is designed to achieve hemostasis-sparing anticoagulation by inhibiting Factor XI.

Which Key Market Players Are Investing In Expansion And Innovation Of Venous Thromboembolism Market?

Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

What Are The Regional Market Dynamics Impacting The Venous Thromboembolism Industry?

North America was the largest region in the venous thromboembolism market in 2024. The regions covered in venous thromboembolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Venous Thromboembolism Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13001&type=smp

Browse Through More Reports Similar to the Global Venous Thromboembolism Market 2025, By The Business Research Company

Blood Transfusion Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

Patient Blood Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report

Anemia And Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795